Back to search

Peptide record

TPDB40583

P02 Anticancer standard
15 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB40583
P02
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 15-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
Sequence
AEEYEFLTPMEEAPK
Physicochemical Analysis
C80H118N16O28S1
RNDCQGHISWV
E
1783.97
3.67
1
5
6
-4
8.93
-0.967
39.33
Mammalian: 4.4 hour Yeast: >20 hour E.coli: >10 hour
1490
83.52
2
Residue Composition
number
2
A
0
R
0
N
0
D
0
C
5
E
0
Q
0
G
0
H
0
I
1
L
1
K
1
M
1
F
2
P
0
S
1
T
0
W
1
Y
0
V
Amino Acid Distribution
A: 2 R: 0 N: 0 D: 0 C: 0 E: 5 Q: 0 G: 0 H: 0 I: 0 L: 1 K: 1 M: 1 F: 1 P: 2 S: 0 T: 1 W: 0 Y: 1 V: 0
Chemical Descriptors
15
C80H118N16O28S1
1783.97
3.67
-4
8.93
-0.967
Free
L
Linear
Free
Anticancer
Rho GDP Dissociation Inhibitor Alpha fragment
Evidence Records 2 records
Evidence 1 Activity

Activity

Relative viability
Relative viability = 0.88 at 50 µg/ml
Anticancer

Target

Bone Cancer
MG-63
Bone

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2023

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

Relative viability
Relative viability = 0.93 at 50 µg/ml
Anticancer

Target

Bone Cancer
U-2 OS
Bone

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2023